Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Medtronic
McKinsey
Merck
Dow

Last Updated: January 24, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for IMC-1C11

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug IMC-1C11?

IMC-1C11 is an investigational drug.

There have been 79 clinical trials for IMC-1C11. The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2015.

The most common disease conditions in clinical trials are Carcinoma, Lung Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Eli Lilly and Company, National Cancer Institute (NCI), and ImClone LLC.

There are sixteen US patents protecting this investigational drug and one hundred and twenty international patents.

Recent Clinical Trials for IMC-1C11
TitleSponsorPhase
Crystalloid Fluid Choice and Neurological Outcome in Patients After Subarachnoid HaemorrhageUniversity Hospital Inselspital, BerneN/A
Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal CancersAsan Medical CenterPhase 2
Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With AtezolizumabImmunocore LtdPhase 1/Phase 2

See all IMC-1C11 clinical trials

Clinical Trial Summary for IMC-1C11

Top disease conditions for IMC-1C11
Top clinical trial sponsors for IMC-1C11

See all IMC-1C11 clinical trials

US Patents for IMC-1C11

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
IMC-1C11   Start Trial Method and compositions for treating cancerous tumors   Start Trial
IMC-1C11   Start Trial Quinolines derivatives as novel anticancer agents GENOSCIENCE PHARMA (Marseilles, FR)   Start Trial
IMC-1C11   Start Trial Asymmetric bisaminoquinolines and bisaminoquinolines with varied linkers as autophagy inhibitors for cancer and other therapy THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (Philadelphia, PA)   Start Trial
IMC-1C11   Start Trial Methods of inducing responsiveness to anti-angiogenic agent Vascular Biogenics Ltd. (Modi'in, IL)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for IMC-1C11

Drugname Country Document Number Estimated Expiration Related US Patent
IMC-1C11 Australia 2014233757 2033-03-18   Start Trial
IMC-1C11 Brazil 112015023948 2033-03-18   Start Trial
IMC-1C11 Canada 2902734 2033-03-18   Start Trial
IMC-1C11 China 105102442 2033-03-18   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
McKinsey
Harvard Business School
Boehringer Ingelheim
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.